|
|
|
|
|
|
|
|
Michael G. Shlipak, MD, MPH
Michael G. Shlipak, MD, MPH, chief of general internal medicine at SFVAMC, was principal investigator of a study that linked tenofovir, one of the most popular and effective HIV/AIDS antiretroviral medications, with a significant risk of kidney damage and kidney disease that increases over time. The elevated risk continued even after patients stopped taking the drug, according to the study of more than 10,000 HIV positive patients in the VA health care system. Dr. Shlipak, a professor of medicine and epidemiology and biostatistics at UCSF, has also led a number of studies advancing the case for Cystatin C, a protein made in cells throughout the body, as a new and more accurate biomarker of kidney disease risk. Cystatin C has consistently identified patients at risk of kidney disease and kidney failure who were missed by the current standard marker.
Learn more
|
|
|
|
|
|
|
|
|
NCIRE » Researchers by Name |
|
|
|
|
|
|
|
|
|